CAR Therapies for Autoimmune Diseases Report

After successfully conquering blood cancers, many CAR therapy developers are now shifting their focus to other immune-mediated disorders like Lupus. These conditions have a high unmet need due to their chronic persistence and lack of effective treatment options.

This report aims to shed light on the latest advancements and understand the future landscape of CAR therapies for the treatment of autoimmune diseases.

Key highlights:

• General momentum in CAR R&D for autoimmune disorders through pipeline and trial growth analyses.

• Detailed analysis of the different approaches taken with autologous and allogeneic CAR-Ts, as well as emerging NK, Macrophage, gamma delta, and T reg programs.

• Identification and profiles of leading drug developers.

Do you have a future market research project that you’d like to discuss with us?